ATTC candidates — IND submission
2026
HUTCHMED plans to initiate global clinical trials for HMPL-A251 around the end of 2025, followed by multiple global Investigational New Drug (IND) filings for more ATTC candidates in 2026.Source filing
HCM biotech catalysts & pipeline
HUTCHMED (CHINA) LTD · Data as of 2026-09-08
Upcoming catalysts
HMPL-A830 — IND submission
H2 2026
Plans for global clinical trial initiation in H2 2026.Source filing
IMG-007 — Topline data
Q4 2027
Phase IIb trial (NCT07037901) in patients with moderate-to-severe atopic dermatitis progressing, with an amended protocol and topline data anticipated in the fourth quarter of 2027.Source filing
IMG-007 — Initial data
2028
Phase II trial initiation in patients with alopecia areata expected in 2026, with initial data expected in 2028.Source filing